AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability

15 Oct 2013

• By Sten Stovall

AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.

AstraZeneca PLC’s biologics unit MedImmune will expand its early oncology pipeline with a new platform to make potent antibody-drug conjugates through the acquisition of U.K.-based Spirogen Ltd. The company announced it has acquired privately-held Spirogen Oct. 15.

AstraZeneca will pay up $200 million upfront and potentially pay out another $240 million based on predefined milestones to gain...